Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RASGRF2 antisense RNA 1 (RASGRF2-AS1)
- Target
- RASGRF2-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Non-coding RNA
01
Overview
RASGRF2 antisense RNA 1 (RASGRF2-AS1) is a long non-coding RNA that originates from the RASGRF2 locus and is transcribed antisense to the protein-coding RASGRF2 gene. It belongs to the class of antisense RNAs, which are known to regulate gene expression by mechanisms including transcriptional interference, modulation of chromatin structure, and acting as competing endogenous RNAs to sequester microRNAs. RASGRF2-AS1 is not known to encode protein, is not a canonical therapeutic target, and currently lacks documented clinical applications, but may play regulatory roles affecting the expression of its sense gene or other targets. Functions of antisense lncRNAs in general include regulation of cell proliferation, migration, epigenetic modulation, and microRNA binding, with implications for processes such as cancer biology.
- Other names
- RASGRF2 antisense RNA 1RASGRF2-AS1CTC-459I6.1Non-coding RNA RASGRF2-AS1NR_105015.1 (NCBI transcript reference)
02
Mechanism of action
Not applicable—no approved drugs with a described mechanism targeting RASGRF2-AS1.
03
Biological functions
Regulation of gene expression (primarily in cis and/or trans via transcriptional and translational effects)MicroRNA sponge (can bind and sequester miRNAs, affecting target gene expression)Chromatin modification and transcriptional interference (general to antisense lncRNAs, though no evidence for RASGRF2-AS1 directly)
04
Disease associations
Potential role in cancer, based on general functions of antisense lncRNAs; direct association with specific diseases for RASGRF2-AS1 has not yet been established, but regulation by lncRNAs including antisense types is implicated in cancer and other diseasesOther (lncRNAs are involved broadly in development, stress responses, and epigenetic regulation)
05
Safety considerations
Not applicable (no evidence for therapeutic development or clinical use that would introduce safety concerns; antisense technologies in general might carry off-target or immune activation risks if developed)
Beyond the preview
Go deeper on RASGRF2 antisense RNA 1 (RASGRF2-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RASGRF2 antisense RNA 1 (RASGRF2-AS1).